2022
DOI: 10.1080/21655979.2022.2067292
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Long noncoding RNAs (lncRNAs) refers to a class of RNAs that have at least 200 nucleotides and do not encode proteins, and the relationship between lncRNA and cancer has recently attracted considerable research attention. The lncRNA FGD5-AS1 is a newly discovered lncRNA with a length of 3772 nucleotides. Studies have found that FGD5-AS1 is abnormally highly expressed in many cancer tissues and was closely related to the lymph node metastasis, tumor invasion, survival time, and recurrence rate of various cancer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 98 publications
0
2
0
Order By: Relevance
“…Although long non-coding RNAs (lncRNAs) do not encode proteins, they can regulate the expression of downstream target protein-coding genes through a variety of mechanisms. Especially for cancer, dysregulation of lncRNAs is associated with various malignant phenotypes and leads to cancer progression and metastasis [ 39 ]. Therefore, the differential expression of miR-4443 in different diseases may be related to the regulation of ceRNA.…”
Section: Discussionmentioning
confidence: 99%
“…Although long non-coding RNAs (lncRNAs) do not encode proteins, they can regulate the expression of downstream target protein-coding genes through a variety of mechanisms. Especially for cancer, dysregulation of lncRNAs is associated with various malignant phenotypes and leads to cancer progression and metastasis [ 39 ]. Therefore, the differential expression of miR-4443 in different diseases may be related to the regulation of ceRNA.…”
Section: Discussionmentioning
confidence: 99%
“…Although early screening and prevention efforts have helped to improve the survival of patients with ESCA, the 5-year overall survival (OS) rate of patients with advanced ESCA remains <20% ( 60 , 61 ). The high mortality and low survival rates of ESCA are currently a major challenge for clinical practitioners and exploring novel biomarkers for prognostic analysis is an important topic in ESCA research ( 62 ). Feng et al ( 63 ) detected a trend toward decreased expression of the lncRNA FAM83H-AS1 in ESCC tissues and cells.…”
Section: Lncrnas and Cancermentioning
confidence: 99%